Canntab Therapeutics achieves major milestone receiving first U.S. patent for multilayer tablets
Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CEO Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has secured protection for their intellectual property receiving a U.S. patent for “Modified Release Multi-Layer Tablet Cannabinoid Formulations.”
Latowsky talks about what that means for the company and moving forward and how they hope to now make a major push to monetize that IP.
Latowsky talks about what that means for the company and moving forward and how they hope to now make a major push to monetize that IP.
People In This Video
No users are tagged in this video
